Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-10 in Symptomatic Oral Lichen Planus
NCT06233591Phase 2Active, not recruiting
- Sponsor
- Lipella Pharmaceuticals
- Start
- Jul 2024
- Primary completion
- Jun 2025
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of liposomal tacrolimus in oral lichen planus (OLP) (3 arms), sponsored by Lipella Pharmaceuticals. Primary endpoint: Safety and Tolerability at 6 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
liposomal tacrolimus
03
Conditions
oral lichen planus (OLP)
Beyond the preview
Go deeper on NCT06233591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233591.